Loading company…
Tesaro develops and commercializes oncology therapies, including PARP inhibitors for ovarian cancer and other malignancies.
Tesaro focused on developing and commercializing oncology medicines, including PARP inhibitors for ovarian cancer and other cancers. Founded in 2010 by Mary Hedley, the company was based in Waltham, US, and is at the Public stage. It raised USD 91.2 mn through a share sale in March 2013 and was later acquired by GlaxoSmithKline Plc for USD 5,100 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in